Acelyrin (SLRN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

SLRN Acelyrin

Watchlist

3.150
-0.070-2.17%

Close Dec 20 16:00 ET

3.150
0.0000.00%

Post 16:13 ET

316.03MMarket Cap-1.19P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5
Moomoo NewsDec 20 13:31 ET · Ratings
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $5
Moomoo NewsDec 19 05:36 ET · Ratings
Hold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales Projections
TipRanksDec 19 05:26 ET · Ratings
Acelyrin Price Target Lowered to $5 From $6 at Morgan Stanley
TipRanksDec 18 21:40 ET
ACELYRIN Is Maintained at Overweight by Wells Fargo
Dow JonesDec 11 10:15 ET · Ratings
Wells Fargo Maintains Overweight on Acelyrin, Lowers Price Target to $13
BenzingaDec 11 10:05 ET · Ratings

Comments

Jaguar8

Dec 10 22:50

🟢 Watchlist WEDNESDAY December 11. NFA

NOTE: I don’t have time to include those in my watchlist which didnt run. Just go back to it because those stocks will go usually after days or a week.
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...

NEWS

$Acelyrin (SLRN.US)$
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
ACELYRIN (Nasdaq: SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis failed to meet its primary endpoint of showing statistically significant improvement in time to treatment failure versus placebo at 24 weeks. Secondary endpoints also did not achieve statistical significance.
Following these results and previous guidance, AC...

Trytosaveabit

Dec 10 15:31

T 1 news halt

$Acelyrin (SLRN.US)$ 🤔

Trytosaveabit

Sep 19 12:15

Not a runner!

$Acelyrin (SLRN.US)$ But sure makes for a nice day! 🥂💵

Heat List

Overall

No Data